Syneos Health [SYENS] vs Tessenderlo Group NV [TESB] Detailed Stock Comparison

Syneos Health
Euronext
Loading...

Tessenderlo Group NV
Euronext
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Syneos Health wins in 7 metrics, Tessenderlo Group NV wins in 10 metrics, with 0 ties. Tessenderlo Group NV appears stronger overall.
View Metrics Details
Vital Metrics Comparison
Metric | Syneos Health | Tessenderlo Group NV | Better |
---|---|---|---|
P/E Ratio (TTM) | 377.86 | 38.36 | Tessenderlo Group NV |
Price-to-Book Ratio | 1.29 | 0.86 | Tessenderlo Group NV |
Debt-to-Equity Ratio | 45.57 | 13.46 | Tessenderlo Group NV |
PEG Ratio | 10.50 | 14.75 | Syneos Health |
EV/EBITDA | 8.25 | 6.35 | Tessenderlo Group NV |
Profit Margin (TTM) | -1.30% | 1.62% | Tessenderlo Group NV |
Operating Margin (TTM) | 10.86% | -0.91% | Syneos Health |
EBITDA Margin (TTM) | 10.86% | N/A | N/A |
Return on Equity | -1.20% | 2.28% | Tessenderlo Group NV |
Return on Assets (TTM) | 3.16% | 0.96% | Syneos Health |
Free Cash Flow (TTM) | $217.00M | $152.60M | Syneos Health |
Dividend Yield | N/A | 2.92% | N/A |
1-Year Return | 12.17% | 14.99% | Tessenderlo Group NV |
Price-to-Sales Ratio (TTM) | 1.20 | 0.61 | Tessenderlo Group NV |
Enterprise Value | $9.79B | $1.65B | Syneos Health |
EV/Revenue Ratio | 1.47 | 0.62 | Tessenderlo Group NV |
Gross Profit Margin (TTM) | 30.87% | 17.68% | Syneos Health |
Revenue per Share (TTM) | $64 | $43 | Syneos Health |
Earnings per Share (Diluted) | $-0.81 | $0.70 | Tessenderlo Group NV |
Beta (Stock Volatility) | N/A | 0.48 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Syneos Health vs Tessenderlo Group NV Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
Stock | 1D | 1W | 1M | 3M | 6M | YTD |
---|---|---|---|---|---|---|
Syneos Health | 0.98% | 10.13% | 13.46% | 22.32% | -2.41% | 11.12% |
Tessenderlo Group NV | -0.19% | 2.09% | 2.87% | 1.51% | 29.40% | 39.55% |
Long-term Returns
Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
---|---|---|---|---|---|---|
Syneos Health | 12.17% | -17.42% | -17.42% | -17.42% | -17.42% | -17.42% |
Tessenderlo Group NV | 14.99% | -10.80% | 0.94% | -21.70% | 21.49% | 21.49% |
Performance & Financial Health Analysis: Syneos Health vs Tessenderlo Group NV
Metric | SYENS | TESB |
---|---|---|
Market Information | ||
Market Cap | €7.98B | €1.62B |
Market Cap Category | Large cap | Large cap |
10 Day Avg. Volume | 197,078 | 13,036 |
90 Day Avg. Volume | 132,790 | 15,923 |
Last Close | €78.04 | €26.85 |
52 Week Range | €53.70 - €84.85 | €18.56 - €27.85 |
% from 52W High | -8.03% | -3.59% |
All-Time High | €109.90 (Dec 11, 2023) | €41.90 (Oct 30, 2017) |
% from All-Time High | -28.99% | -35.92% |
Growth Metrics | ||
Quarterly Revenue Growth | -0.08% | -0.03% |
Quarterly Earnings Growth | 0.72% | -0.31% |
Financial Health | ||
Profit Margin (TTM) | -0.01% | 0.02% |
Operating Margin (TTM) | 0.11% | -0.01% |
Return on Equity (TTM) | -0.01% | 0.02% |
Debt to Equity (MRQ) | 45.57 | 13.46 |
Cash & Liquidity | ||
Book Value per Share (MRQ) | €60.47 | €31.35 |
Cash per Share (MRQ) | €12.85 | €4.17 |
Operating Cash Flow (TTM) | €749.00M | €333.20M |
Levered Free Cash Flow (TTM) | €451.50M | €170.94M |
Dividends | ||
Last 12-Month Dividend Yield | N/A | 2.92% |
Last 12-Month Dividend | N/A | €0.75 |
Valuation & Enterprise Metrics Analysis: Syneos Health vs Tessenderlo Group NV
Metric | SYENS | TESB |
---|---|---|
Price Ratios | ||
P/E Ratio (TTM) | 377.86 | 38.36 |
Forward P/E | 10.50 | 14.75 |
PEG Ratio | 10.50 | 14.75 |
Price to Sales (TTM) | 1.20 | 0.61 |
Price to Book (MRQ) | 1.29 | 0.86 |
Market Capitalization | ||
Market Capitalization | €7.98B | €1.62B |
Enterprise Value | €9.79B | €1.65B |
Enterprise Value Metrics | ||
Enterprise to Revenue | 1.47 | 0.62 |
Enterprise to EBITDA | 8.25 | 6.35 |
Risk & Other Metrics | ||
Beta | N/A | 0.48 |
Book Value per Share (MRQ) | €60.47 | €31.35 |
Financial Statements Comparison: Syneos Health vs Tessenderlo Group NV
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
Metric (MRQ) | SYENS | TESB |
---|---|---|
Revenue/Sales | €1.68B | €346.10M |
Cost of Goods Sold | €1.16B | €284.90M |
Gross Profit | €514.00M | €61.20M |
Research & Development | €78.00M | N/A |
Operating Income (EBIT) | €147.00M | €3.10M |
EBITDA | €306.00M | €-53.40M |
Pre-Tax Income | €29.00M | €-16.70M |
Income Tax | €27.00M | €1.10M |
Net Income (Profit) | €2.00M | €-17.80M |
Balance Sheet & Liquidity Metrics (MRQ)
Metric (MRQ) | SYENS | TESB |
---|---|---|
Cash & Equivalents | €579.00M | €182.40M |
Total Current Assets | €3.28B | €1.27B |
Total Current Liabilities | €2.07B | €599.70M |
Long-Term Debt | €1.77B | €134.10M |
Total Shareholders Equity | €7.27B | €1.91B |
Retained Earnings | €4.77B | N/A |
Property, Plant & Equipment | €3.85B | €704.50M |
Cash Flow Statement Comparison (MRQ)
Metric (MRQ) | SYENS | TESB |
---|---|---|
Operating Cash Flow | €40.00M | €15.30M |
Capital Expenditures | €-143.00M | €-22.70M |
Free Cash Flow | €9.00M | €-12.90M |
Debt Repayment | €-166.00M | €43.70M |
Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
Metric | SYENS | TESB |
---|---|---|
Shares Short | N/A | N/A |
Short Ratio | N/A | N/A |
Short % of Float | N/A | N/A |
Average Daily Volume (10 Day) | 197,078 | 13,036 |
Average Daily Volume (90 Day) | 132,790 | 15,923 |
Shares Outstanding | 103.45M | 60.49M |
Float Shares | 69.83M | 19.65M |
% Held by Insiders | 0.31% | 0.67% |
% Held by Institutions | 0.28% | 0.06% |
Dividend Analysis & Yield Comparison: Syneos Health vs Tessenderlo Group NV
Metric | SYENS | TESB |
---|---|---|
Last 12-Month Dividend | N/A | €0.75 |
Last 12-Month Dividend Yield | N/A | 2.92% |
3-Year Avg Annual Dividend | N/A | €0.75 |
3-Year Avg Dividend Yield | N/A | 2.85% |
3-Year Total Dividends | N/A | €2.25 |
Ex-Dividend Date | N/A | Jun 04, 2025 |